Levels of antiangiogenic factors in preeclamptic pregnancies

Growth Factors

Volumn 28, Issue 4, 2010, Pages 293-298

  Zhao, Wenqiu ^a   Qiao, Jie ^a   Zhang, Qiufang ^a   Zhao, Yangyu ^a   Chen, Qi ^b,c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antiangiogenic factor; FGR; Preeclampsia; SEndoglin; SFlit 1

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEAN ARTERIAL PRESSURE; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; STATISTICAL SIGNIFICANCE;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD; BLOOD PRESSURE; FEMALE; FETAL GROWTH RETARDATION; GENE EXPRESSION; HUMANS; HYPERTENSION; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77957817400     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977191003662651     Document Type: Article

References (25)

1. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884e91.
2. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. 2008. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 199: 266e1-266e6.
3. Catarino C, Rebelo I, Belo L, Rocha S, Castro EB, Patŕicio B, Quintanilha A, Santos-Silva A. 2009. Fetal and maternal angiogenic/anti- angiogenic factors in normal and preeclamptic pregnancy. Growth Factors 27:345-351.
4. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. 2008. How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 107:196-208.
5. Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. 2008. Maternal death in the 21st century: Causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 1999:36:e31-e35.
6. Gu Y, Lewis DF, Wang Y. 2008. Placental productions and expressions of sEndoglin, sFlt-1, and PlGF in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 93: 260-266.
7. Hirashima C, Ohkuchi A, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. 2008. Alteration ofserum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res 31:1541-1548.
8. Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A. 2008. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 29:555-563.
9. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. 2009. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29: 464-470.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
11. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992-1005.
12. Maynard SE, Min JY Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658.
13. Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH. 2002. Second-trimester uterine artery Doppler screening in unselected populations: A review. J Matern Fetal Neonatal Med 12:78-88.
14. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. 2007. Sequential changes in antiangio-genic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137-142.
15. Redman CW, Sargent IL. 2005. Latest advances in understanding preeclampsia. Science 308:1592-1594.
16. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. 1989. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 161:1200-1204.
17. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. 2008. A longitudinal study ofangiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endo-thelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21: 9-23.
18. Schlembach D, Wallner W, Sengenberger R. 2007. Angiogenic growth factor levels in maternal and fetal blood: Correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 29:407-413.
19. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM. 2005. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 90: 4895-4903.
20. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5:519-524.
21. Stepan H, Geide A, Faber R. 2004. Soluble fms-like tyrosine kinase 1. N Engl J Med 351:2241-2242.
22. Stepan H, Unversucht A, Wessel N, Faber R. 2007a. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49:818-824.
23. Stepan H, Kramer T, Faber R. 2007b. Maternal plasma concentrations of soluble endoglin in pregnancies with intrau-terine growth restriction. J Clin Endocrinol Metab 92: 2831-2834.
24. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, DAmore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. 2006. Soluble endoglin contributes to the pathogenesis of preeclamp-sia. Nat Med 12:642-649.
25. Walther T Wallukat G, Jank A. 2005. AT1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 46:1275-1279.